Cultured transgenic cell allowing growth of norovirus, and use thereof

Patent metadata

Field	Value
Publication number	US-11299750-B2
Application number	US-201716074648-A
Country	US
Kind code	B2
Filing date	Feb 1, 2017
Priority date	Feb 3, 2016
Publication date	Apr 12, 2022
Grant date	Apr 12, 2022

Abstract

An object of the present invention is to solve problems in terms of stagnation of research on norovirus by providing a cultured transgenic cell or a transgenic animal in which murine norovirus (MNV) can be grown across the barrier of host specificity in mammalian cells, and providing a screening method that uses the cultured transgenic cell or the transgenic animal. The present inventors have found that MNV infection is determined in a cultured transgenic mammalian cell or a mammal possessing the cultured transgenic mammalian cell as its own cell, the cultured transgenic mammalian cell containing one or more species selected from the entirety or a portion of the murine CD300F gene and/or a CD300 family gene having an extracellular domain nucleotide sequence similar to that of the murine CD300F gene. The present inventors have solved the aforementioned problems by providing, for example, a norovirus-related drug screening method on the basis of this finding.

First claim

The invention claimed is:

1. A cultured transgenic mammalian cell, wherein said cell comprises a nucleotide sequence that encodes a polypeptide comprising an amino acid sequence having 80% or more sequence identity to residues 31-137 of SEQ ID NO: 2, and
wherein the cell is infected with murine norovirus.

2. The cultured transgenic mammalian cell according to claim 1 , wherein said polypeptide contains all β-coil structure domains that the polypeptide of SEQ ID NO: 2 does.

3. The cultured transgenic mammalian cell according to claim 1 , wherein said polypeptide contains a transmembrane domain.

4. The cultured transgenic mammalian cell according to claim 3 , wherein said polypeptide contains an intracellular domain having a signaling function.

5. The cultured transgenic mammalian cell according to claim 1 , wherein said polypeptide comprises the extracellular domain of murine CD300d or murine CD300f, wherein said murine CD300d has the amino acid sequence of SEQ ID NO: 6, and wherein said murine CD300f has the amino acid sequence of SEQ ID NO: 2.

6. The cultured transgenic mammalian cell according to claim 3 , wherein said polypeptide does not contain an intracellular domain having a signaling function.

7. The cultured transgenic mammalian cell according to claim 1 , wherein said nucleotide sequence encodes a polypeptide comprising residues 1-150 of SEQ ID NO: 2.

8. The cultured transgenic mammalian cell according to claim 1 , wherein the cultured mammalian cell is a cultured cell line, an organoid derived from a biopsy sample, an immortalized cell, or an iPS cell.

9. The cultured transgenic mammalian cell according to claim 1 , wherein the cultured mammalian cell is a human cell, a mouse cell, a rat cell, a hamster cell, a guinea pig cell, a rabbit cell, a cat cell, a dog cell, a pig cell, or a monkey cell.

10. The cultured transgenic mammalian cell according to claim 9 , wherein the cultured mammalian cell is an HEK293T cell, a Caco2 cell, an Intestine407 cell, a cultured macrophagic 15310-LN cell, an NALM-6 cell, an RAW264.7 cell, an NIH3T3 cell, an M1 cell, a BHK cell, a CHO cell, a CRFK cell, a MDCK cell, a PK-15 cell, a VERO cell, or a COS7 cell.

Assignees

• Japan As Represented By Director General Of Nat Institute Of Infectious Diseases
• Denka Company Ltd
• Nat Ct Geriatrics & Gerontology
• Director General Of Nat Institute Of Infectious Diseases

Inventors

• HAGA Kei
• Fujimoto Akira
• Todaka Reiko
• Katayama Kazuhiko
• Nakanishi Akira
• Miki Motohiro
• Sekine Sakari
• Otsuka Hiroshi
• Mimori Shigetaka

Classifications

• G01N33/5088 Primary

  of vertebrates · CPC title

• C12Q1/02

  involving viable microorganisms · CPC title

• G01N2333/08

  RNA viruses · CPC title

• C07K14/70503

  Immunoglobulin superfamily · CPC title

• G01N33/50

  Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q) · CPC title